Policy

Selegiline hydrochloride (HCl) (Zelapar®) is indicated as an adjunct therapy in the management of Parkinson's disease for individuals being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline HCl (Zelapar®) has any beneficial effect in the absence of concurrent levodopa therapy.

The use of selegiline HCl (Zelapar®) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description

Selegiline HCl (Zelapar®) is best known as an irreversible inhibitor of monoamine oxidase (MAO). Selegiline HCl (Zelapar®) inhibits MAO by acting as a “suicide” substrate for the enzyme; that is, selegiline HCl (Zelapar®) is converted by MAO to an active moiety that combines irreversibly with the active site or with the enzyme's essential flavin adenine dinucleotide (FAD) cofactor. Because selegiline HCl (Zelapar®) has greater affinity for type B active sites than for type A active sites, it can serve as a selective inhibitor of MAO type B if it is administered at the recommended dose. Inhibition of MAO type B activity is generally considered to be of primary importance. In addition, there is evidence that selegiline HCl (Zelapar®) may act through other mechanisms by inhibiting the re-uptake of dopamine at the synapse to increase dopaminergic activity. Selegiline HCl (Zelapar®) is the orally disintegrating formulation.
of selegiline HCl and is designed to provide greater efficacy at lower doses of selegiline HCl.

**Policy Guideline Inclusion**

Selegiline hydrochloride (HCl) (Zelapar®) is approved when all of the following inclusion criteria are met:

- Documentation of Parkinson’s disease
- Documentation of the trial and failure of, intolerance to, or contraindication to other oral non-disintegrating formulations of selegiline HCl

**Policy Guideline Exclusion**

Selegiline HCl (Zelapar®) is denied when any of the following exclusion criteria are present:

- No documentation of Parkinson’s disease
- No documentation of the trial and failure of, intolerance to, or contraindication to other oral non-disintegrating formulations of selegiline HCl

**Policy List of Applicable Drugs**

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zelapar</td>
<td>selegiline hydrochloride</td>
</tr>
</tbody>
</table>

**Dosing and Administration**

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

**Policy References**


**Policy Link to Related Policies**
